Connect Biopharma Holdings Limited (CNTB) Revenue History
Annual and quarterly revenue from 2019 to present
CNTB Revenue Over Time (2019–2025)
CNTB Revenue Growth History
0 of 1 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- -99.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $0 | -100.0% |
| Q2 2025 | $48K | -99.8% |
| Q4 2024 | $698K | — |
| Q2 2024 | $24.1M | — |
| Q4 2023 | $0 | — |
| Q2 2023 | $0 | — |
| Q4 2022 | $0 | — |
| Q2 2022 | $0 | — |
Revenue Breakdown (FY 2025)
CNTB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CNTB Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 29, 2026, Connect Biopharma Holdings Limited (CNTB) generated trailing twelve-month (TTM) revenue of $24.9 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue, down 100.0% sequentially.
Historical Growth Trajectory
CNTB's historical revenue data shows various trends over time. Connect Biopharma Holdings Limited's highest annual revenue of $26.0 million was recorded in 2024.
Revenue by Segment
CNTB's revenue is primarily driven by License (100%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ABBV (+9.5% YoY), REGN (+5.9% YoY), and ARQT (+95.3% YoY) — CNTB has underperformed the peer group in revenue growth. Compare CNTB vs ABBV →
CNTB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CNTBCurrent | $25M | -100.0% | - | -90740.6% | |
 ABBV | $61.2B | +9.5% | +6.0% | 32.8% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 DAWN | $158M | +20.6% | - | -80.8% | |
 RXST | $134M | -19.5% | +55.7% | -35.8% |
CNTB Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $64K | -99.8% | $64K | 100.0% | $-58,074,000 | -90740.6% |
| 2024 | $26.0M | - | $26.0M | 100.0% | $-22,452,000 | -86.2% |
| 2023 | $0 | - | $0 | - | $-69,056,000 | - |
| 2022 | $0 | - | $0 | - | $-119,316,000 | - |
| 2021 | $0 | - | $0 | - | $-98,107,000 | - |
| 2020 | $0 | - | $0 | - | $-30,295,313 | - |
| 2019 | $0 | - | $0 | - | $-15,993,449 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CNTB — Frequently Asked Questions
Quick answers to the most common questions about buying CNTB stock.
Is CNTB's revenue growth accelerating or slowing?
CNTB revenue is declining -100.0% year-over-year. TTM revenue fell to $25M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is CNTB's revenue history from 2019 to 2026?
Connect Biopharma Holdings Limited (CNTB) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $25M, growing at -100.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CNTB's long-term revenue growth rate (CAGR)?
Connect Biopharma Holdings Limited's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CNTB.
Why does CNTB's quarterly revenue fluctuate?
CNTB quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Connect Biopharma Holdings Limited's revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is CNTB's revenue distributed by segment?
CNTB reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CNTB's revenue compare to industry peers?
Connect Biopharma Holdings Limited (CNTB) with TTM revenue of $25M and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.